TC
NBIX icon

Truvestments Capital’s Neurocrine Biosciences NBIX Stock Holding History

Truvestments Capital’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$5.9K Buy
35
+7
+25% +$1.04K ﹤0.01% 873
2026
Q1 		$3.69K Sell
28
-24
-46% -$3.18K ﹤0.01% 929
2025
Q4 		$7.38K Sell
52
-22
-30% -$3.19K ﹤0.01% 743
2025
Q3 		$10.4K Sell
74
-225
-75% -$30.5K ﹤0.01% 712
2025
Q2 		$37.6K Hold
299
– – 0.01% 442
2025
Q1 		$33.1K Sell
299
-259
-46% -$32.8K 0.01% 471
2024
Q4 		$76.2K Buy
558
+14
+3% +$1.73K 0.02% 312
2024
Q3 		$62.7K Buy
+544
New +$74.6K 0.02% 333
2024
Q2 		– Sell
-566
Closed -$78.1K – 510
2024
Q1 		$78.1K Buy
566
+298
+111% +$40.7K 0.03% 311
2023
Q4 		$35.3K Hold
268
– – 0.02% 362
2023
Q3 		$30.1K Hold
268
– – 0.02% 338
2023
Q2 		$25.3K Hold
268
– – 0.01% 358
2023
Q1 		$27.1K Hold
268
– – 0.01% 348
2022
Q4 		$32K Sell
268
-845
-76% -$99K 0.02% 341
2022
Q3 		$118K Hold
1,113
– – 0.07% 190
2022
Q2 		$108K Buy
+1,113
New +$103K 0.06% 200
2022
Q1 		– Sell
-1,226
Closed -$104K – 404
2021
Q4 		$104K Buy
1,226
+195
+19% +$17.9K 0.05% 208
2021
Q3 		$99K Buy
1,031
+34
+3% +$3.21K 0.05% 201
2021
Q2 		$97K Buy
997
+224
+29% +$21.5K 0.05% 202
2021
Q1 		$75K Buy
773
+495
+178% +$51.9K 0.04% 241
2020
Q4 		$26K Buy
+278
New +$26.9K 0.02% 327
2020
Q3 		– Sell
-80
Closed -$9K – 463
2020
Q2 		$9K Buy
80
+11
+16% +$1.22K 0.01% 387
2020
Q1 		$5K Buy
+69
New +$6.75K 0.01% 418
2019
Q4 		– Sell
-38
Closed -$3K – 419
2019
Q3 		$3K Buy
+38
New +$3.55K ﹤0.01% 638

Other funds holding NBIX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Truvestments Capital's NBIX Position: Q2 2026 in Review

Truvestments Capital increased its Neurocrine Biosciences (NBIX) stake by 25% in Q2 2026, buying an estimated $1.04K and bringing the position to 35 shares worth $5.9K. The position accounts for ﹤0.01% of the portfolio, ranked #873.

Truvestments Capital first reported a position in NBIX in Q3 2019 and has held it in 24 quarters since. The position peaked at $118K in Q3 2022. 781 funds tracked by Wall St. Rank hold NBIX as of Q2 2026.

  • Truvestments Capital held 35 shares of Neurocrine Biosciences worth $5.9K as of Q2 2026.
  • Truvestments Capital bought 7 Neurocrine Biosciences shares in Q2 2026, an estimated $1.04K.
  • Neurocrine Biosciences made up ﹤0.01% of Truvestments Capital's portfolio in Q2 2026, its #873 holding.
  • Truvestments Capital first reported a position in Neurocrine Biosciences in Q3 2019 and has held it in 24 quarters since.
  • Truvestments Capital's Neurocrine Biosciences position peaked at $118K in Q3 2022.
  • 781 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2026.

Based on Truvestments Capital's 13F filing for Q2 2026, filed 12 Aug 2026.